<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Erythropoietins; Epoetin; Anaemias: chronic renal failure; Darbepoetin; Methoxy polyethylene glycol-epoetin beta" /><meta name="IX" content="Erythropoietins; Epoetin; Anaemias: chronic renal failure; Darbepoetin; Methoxy polyethylene glycol-epoetin beta" /><title>Erythropoietins: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5880-erythropoietins.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5880-erythropoietins.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5880-erythropoietins.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5812-nutrition-and-blood.htm">9 Nutrition and blood</a> &gt; <a href="PHP5813-anaemias-and-some-other-blood-disorders.htm">9.1 Anaemias and some other blood disorders</a> &gt; <a href="PHP5877-drugs-used-in-hypoplastic-haemolytic-and-renal-anaemias.htm">9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5877-drugs-used-in-hypoplastic-haemolytic-and-renal-anaemias.htm" title="Previous: 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5886-darbepoetin-alfa.htm" title="Next: DARBEPOETIN ALFA">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a301064.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Darbepoetin Alfa</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Blood Formation, Coagulation, and Thrombosis 20:00 &gt; Hematopoietic Agents 20:16</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a392034.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Epoetin Alfa</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Blood Formation, Coagulation, and Thrombosis 20:00 &gt; Hematopoietic Agents 20:16</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts (5)</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/22839-k.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Darbepoetin</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: D &gt; Interactions of Darbepoetin</p></div></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/12049-k.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Epoetin alfa</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: E &gt; Interactions of Epoetin alfa</p></div></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/13785-e.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Epoetin beta</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: E &gt; Interactions of Epoetin beta</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22erythropoietins%22%22epoetin%22%22anaemias%22%22darbepoetin%22%22methoxy+polyethylene+glycol-epoetin+beta%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (5)</a></li></ul><ul><li><h3>British National Formulary (17)</h3></li><li><a href="PHP5813-anaemias-and-some-other-blood-disorders.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1 Anaemias and some other blood disorders</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 9 Nutrition and blood</p></div></li><li><a href="PHP5814-iron-deficiency-anaemias.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1.1 Iron-deficiency anaemias</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders</p></div></li><li><a href="PHP5867-drugs-used-in-megaloblastic-anaemias.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1.2 Drugs used in megaloblastic anaemias</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22erythropoietins%22%22epoetin%22%22anaemias%22%22darbepoetin%22%22methoxy+polyethylene+glycol-epoetin+beta%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (17)</a></li></ul><ul><li><h3>BNF for Children (14)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13879-anaemias-and-some-other-blood-disorders.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1 Anaemias and some other blood disorders</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13880-iron-deficiency-anaemias.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1.1 Iron-deficiency anaemias</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13906-drugs-used-in-megaloblastic-anaemias.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1.2 Drugs used in megaloblastic anaemias</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22erythropoietins%22%22epoetin%22%22anaemias%22%22darbepoetin%22%22methoxy+polyethylene+glycol-epoetin+beta%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (14)</a></li></ul><ul><li><h3>Handbook on Injectable Drugs</h3></li><li><a href="http://www.medicinescomplete.com/mc/hid/2010/a597003.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Epoetin Alfa</a><div class="breadcrumb"><p><strong>Handbook on Injectable Drugs</strong> &gt; Monographs &gt; E</p></div></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/e10-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Erythropoietins (epoetins, recombinant human erythropoietins)</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; E</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference (4)</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/1210-a8-z.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Anaemias</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Blood Products Plasma Expanders and Haemostatics</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/20270-f.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Darbepoetin Alfa</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Blood Products Plasma Expanders and Haemostatics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/ms-16635-r.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Epoetins</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Blood Products Plasma Expanders and Haemostatics &gt; Drug Monographs</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22erythropoietins%22%22epoetin%22%22anaemias%22%22darbepoetin%22%22methoxy+polyethylene+glycol-epoetin+beta%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (4)</a></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/02824.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Darbepoetin Alfa</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; D &gt; DA</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy (5)</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/c12-sec1-009.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Nomenclature for Various Special Products</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 1: The Science of Pharmacy &gt; Section 2: Pharmaceutical Chemistry &gt; 12 Drug Nomenclature—United States Adopted Names</p></div></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/c49-sec1-003.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Unique Pharmaceutical Challenges of Biotechnology-Derived Therapeutics</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 1: The Science of Pharmacy &gt; Section 5: Pharmaceutical Dosage Forms: Manufacturing and Compounding &gt; 49 Biotechnology and Drugs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/c56-sec1-002.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Triggering Inflammatory Response</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 1: The Science of Pharmacy &gt; Section 6: Pharmacokinetics and Pharmacodynamics &gt; 56 Principles of Immunology</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22erythropoietins%22%22epoetin%22%22anaemias%22%22darbepoetin%22%22methoxy+polyethylene+glycol-epoetin+beta%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (5)</a></li></ul><ul><li><h3>Stockley's Drug Interactions (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E4E3E0R0D1694.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Darbepoetin alfa</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; D</p></div></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E2E3E0R0D1694.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Epoetin alfa</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; E</p></div></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E6E3E0R0D1694.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Epoetins</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; E</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>Erythropoietins</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Epoetins</strong> (recombinant human erythropoietins) are used to treat symptomatic anaemia associated with erythropoietin deficiency in chronic renal failure, to increase the yield of autologous blood in normal individuals and to shorten the period of symptomatic anaemia in patients receiving cytotoxic chemotherapy. Epoetin beta is also used for the prevention of anaemia in preterm neonates of low birth-weight; only unpreserved formulations should be used in neonates because other preparations may contain benzyl alcohol (see <a title="target-block: Excipients" href="PHP60-general-guidance.htm#PHP64">Excipients</a>).</p> <p><strong>Darbepoetin</strong> is a hyperglycosylated derivative of epoetin; it has a longer half-life and can be administered less frequently than epoetin.</p> <p><strong>Methoxy polyethylene glycol-epoetin beta</strong> is a continuous erythropoietin receptor activator that is licensed for the treatment of symptomatic anaemia associated with chronic kidney disease. It has a longer duration of action than epoetin.</p> <p id="PHP5881">Other factors, such as iron or folate deficiency, that contribute to the anaemia of chronic renal failure should be corrected before treatment and monitored during therapy. Supplemental iron may improve the response in resistant patients. Aluminium toxicity, concurrent infection, or other inflammatory disease can impair the response to erythropoietin.</p> <div class="cI" id="PHP5882"><h3 class="cT">MHRA/CHM advice (December 2007) Erythropoietins—haemoglobin concentration</h3><p>Overcorrection of haemoglobin concentration in patients with chronic kidney disease may increase the risk of death and serious cardiovascular events, and in patients with cancer may increase the risk of thrombosis and related complications:</p><ul><li><p>patients should not be treated with erythropoietins for the licensed indications in chronic kidney disease or cancer in patients receiving chemotherapy <em>unless</em> symptoms of anaemia are present;</p> </li><li><p>the haemoglobin concentration should be maintained within the range 10–12 g/100 mL;</p> </li><li><p>haemoglobin concentrations higher than 12 g/100 mL should be avoided;</p> </li><li><p>the aim of treatment is to relieve symptoms of anaemia, and in patients with chronic kidney disease to avoid the need for blood transfusion; the haemoglobin concentration should not be increased beyond that which provides adequate control of symptoms of anaemia (in some patients, this may be achieved at concentrations lower than the recommended range).</p> </li></ul><p>See also MHRA/CHM advice below.</p></div> <div class="cI" id="PHP5883"><h3 class="cT">MHRA/CHM advice (December 2007 and July 2008) Erythropoietins—tumour progression and survival in patients with cancer</h3><p>Clinical trial data show an unexplained excess mortality and increased risk of tumour progression in patients with anaemia associated with cancer who have been treated with erythropoietins. Many of these trials used erythropoietins <em>outside</em> of the licensed indications (i.e. overcorrected haemoglobin concentration or given to patients who have <em>not</em> received chemotherapy):</p><ul><li><p>erythropoietins licensed for the treatment of <em>symptomatic</em> anaemia associated with cancer, are licensed only for patients who are receiving chemotherapy;</p> </li><li><p>the decision to use erythropoietins should be based on an assessment of the benefits and risks for individual patients; blood transfusion may be the preferred treatment for anaemia associated with cancer chemotherapy, particularly in those with a good cancer prognosis.</p> </li></ul><p>See also MHRA/CHM advice above.</p></div> <div class="cI" id="PHP5884"><h3 class="cT">Pure red cell aplasia</h3><p>There have been very rare reports of pure red cell aplasia in patients treated with erythropoietins. In patients who develop a lack of efficacy with erythropoietin therapy and with a diagnosis of pure red cell aplasia, treatment with erythropoietins must be discontinued and testing for erythropoietin antibodies considered. Patients who develop pure red cell aplasia should <strong>not</strong> be switched to another form of erythropoietin.</p></div> <div id="PHP5885" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Epoetin alfa, beta and darbepoetin alfa for cancer treatment-induced anaemia (May 2008)</h3><p>Erythropoietin analogues are <strong>not</strong> recommended for routine use in the management of cancer treatment-induced anaemia, but may be considered, in combination with intravenous iron, for:</p><ul><li><p>women receiving platinum-based chemotherapy for ovarian cancer who have symptomatic anaemia with a haemoglobin concentration of 8 g/100 mL or lower (the use of erythropoietin analogues does not preclude the use of existing approaches to the management of anaemia, including blood transfusion when necessary);</p> </li><li><p>patients who cannot be given blood transfusions and who have profound cancer treatment-related anaemia that is likely to have an impact on survival.</p> </li></ul><p>Patients currently treated with erythropoietin analogues for the management of cancer treatment-related anaemia who do not fulfil the criteria outlined above can continue therapy until they and their specialists consider it appropriate to stop.</p></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5886-darbepoetin-alfa"><a href="PHP5886-darbepoetin-alfa.htm" title="DARBEPOETIN ALFA">DARBEPOETIN ALFA</a></li><li id="_PHP5888-epoetin-alfa-beta-theta-and-zeta"><a href="PHP5888-epoetin-alfa-beta-theta-and-zeta.htm" title="EPOETIN ALFA, BETA, THETA, and ZETA">EPOETIN ALFA, BETA, THETA, and ZETA</a></li><li id="_PHP5906-methoxy-polyethylene-glycol-epoetin-beta"><a href="PHP5906-methoxy-polyethylene-glycol-epoetin-beta.htm" title="METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA">METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5877-drugs-used-in-hypoplastic-haemolytic-and-renal-anaemias.htm">Previous: 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias</a> | <a class="top" href="PHP5880-erythropoietins.htm#">Top</a> | <a accesskey="]" href="PHP5886-darbepoetin-alfa.htm">Next: DARBEPOETIN ALFA</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>